Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Johnston, S.Toi, M.O'Shaughnessy, J.Rastogi, P.Campone, M.Neven, P.Huang, C. S.2024-06-122024-06-1220230960-97761532-3080https://hdl.handle.net/20.500.14551/26828[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomesConference Object68S22S23N/AWOS:001037996400040